アバコパン
“Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis”. J Am Soc Nephrol 28 (9): 2756–2767. (September 2017). doi:10.1681/ASN.2016111179. PMC 5576933. PMID 28400446. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576933/.
“Avacopan for the Treatment of ANCA-Associated Vasculitis”. N Engl J Med 384 (7): 599–609. (February 2021). doi:10.1056/NEJMoa2023386. PMID 33596356.
“Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial”.